covalent chemistry
Novartis Bets on Covalent Chemistry in $1B Matchpoint Therapeutics Deal
Novartis; Matchpoint Therapeutics; covalent chemistry; exclusive option and license agreement; inflammatory diseases; oral inhibitors; Advanced Covalent Exploration platform; drug development; biotechnology partnerships